DIRS.INFO The most relevant business & tech news

☆ Novo Nordisk and Eli Lilly rival soars 32% after promising weight-loss drug results
▼ + stars: | 2024-02-26 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Vials move along a conveyor at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Monday, June 12, 2023. Shares of Denmark's Zealand Pharma rocketed higher, after the company posted strong results from a trial of a liver disease treatment that has been touted as a potential competitor in the booming weight-loss drug market. The drug has "demonstrated efficacy" in people with obesity and is currently undergoing five Phase-3 trials in a clinical program for people who are overweight or obese. Analysts latched onto the drug's possible efficacity in obesity research following the latest test results, which indicated the safety of the top dosage used in that trial. Several other firms, including Eli Lilly, Roche and AstraZeneca, also seek to compete in the sector.

Persons: Ozempic, Eli Lilly, Roche Organizations: Novo Nordisk, pharma, Denmark's Zealand Pharma, U.S . Food, Drug Administration, Zealand Pharma, Nordisk, AstraZeneca Locations: Hillerod, Denmark, U.S, London, Danish

☆ Macron to unveil 2.1 bln eur Novo Nordisk pharma investment in France
▼ + stars: | 2023-11-23 | by ( ) www.reuters.com time to read: +1 min

The logo of Danish drugmaker Novo Nordisk in their offices in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little Acquire Licensing RightsPARIS, Nov 23 (Reuters) - French President Emmanuel Macron will on Thursday inaugurate a 2.1 billion euro ($2.3 billion) investment by Danish pharmaceutical company Novo Nordisk (NOVOb.CO) in France, his office said, pitching it as a sign of newly restored French industrial competitiveness. The investment, for which no detail was provided by Macron's office, will be based in Chartres, west of Paris, where Novo already employs nearly 2,000 people. The Elysee palace deemed it the most significant investment in the health sector of Macron's mandates so far and said it would create 500 jobs. ($1 = 0.9168 euros)Reporting by Michel Rose, Editing by Dominique VidalonOur Standards: The Thomson Reuters Trust Principles.

Persons: Tom Little, Emmanuel Macron, Michel Rose, Dominique Vidalon Organizations: Novo Nordisk, REUTERS, Rights, Thomson Locations: Danish, Hillerod, Denmark, France, Chartres, Paris

☆ Fresenius Medical: effect of drugs like Ozempic on patient numbers is neutral
▼ + stars: | 2023-10-12 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

Pens for the diabetes drug Ozempic sit on a production line at Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. "Based on currently available clinical data and scientific evidence, Fresenius Medical Care assesses the overall effect of GLP-1 analog use on its own patient flow model as neutral," it said in a statement to Reuters. Novo said on Wednesday that the Ozempic trial was stopped ahead of schedule because independent supervisors had ruled the drug's positive effect on chronic kidney disease had become clear enough. In its statement, Fresenius Medical said that the early termination of the study, known as FLOW, does not allow for clear conclusions. Earlier on Thursday, rival DaVita (DVA.N) said that Novo's FLOW trial would only have a limited impact on overall dialysis patient numbers.

Persons: Tom Little, DaVita, Novo, Fresenius, Ludwig Burger, Jane Merriman, Kirsten Donovan Organizations: REUTERS, Rights, Novo Nordisk's, Reuters, Thomson Locations: Hillerod, Denmark

☆ Novo Nordisk stops Ozempic kidney trial after early signs of success
▼ + stars: | 2023-10-10 | by ( Patrick Wingrove | ) www.reuters.com time to read: +2 min

Pens for the diabetes drug Ozempic sit on a production line to be packaged at Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. Novo said the trial would be halted almost a year early based on a recommendation from the independent data monitoring board overseeing the study. Independent monitors can recommend stopping a trial early if there is clear evidence that a drug was going to succeed or fail based on interim analyses. Semaglutide is also the active ingredient in Novo Nordisk's powerful weight-loss drug Wegovy. Novo's success has also created an economic boom for Denmark, according to Danish economists, analysts, and executives at the Novo Nordisk Foundation.

Persons: Tom Little, Novo, Danish drugmaker, Wegovy, Emily Field, Patrick Wingrove, Sriparna Roy, Bill Berkrot Organizations: REUTERS, Novo Nordisk, Barclays, Novo Nordisk Foundation, Thomson Locations: Hillerod, Denmark, Danish, New York, Bengaluru

Search resuls for: "Hillerod"

4 mentions found